FIDAS-3

Research use only, not for human use.

FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.

FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities. FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A).

FIDAS-3 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells. FIDAS-3 (3-10 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-3 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-3 (10 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosyl homocysteine (SAH) in LS174T cells.Cell Viability Assay Cell Line:LS174T colorectal cancer (CRC) cells Concentration:3 μM Incubation Time:7 days Result:Significantly inhibited the proliferation of LS174T cells.

FIDAS-3 (20 mg/kg; intraperitoneal injection; daily; for one months; C57BL/6J athymic nude mice) treatment significantly inhibits the growth of xenograft tumors. Animal Model:C57BL/6J athymic nude mice (6-8 week) injected with LS174 cells Dosage:20 mg/kg Administration:Intraperitoneal injection; daily; for one months Result:Significantly inhibited the growth of xenograft tumors.

——

Wnt/Notch/Hedgehog

Wnt/beta/catenin

MAT2A|MATA2|Wnt

——

——

1266684-01-8

259.29

C16H15F2N

>98% (HPLC)

DMSO:90mg/ml(347.10mM; Need ultrasonic)

CN(C)C1=CC=C(/C=C/C2=C(F)C=CC=C2F)C=C1

——

(-20℃)

With Ice Pack

≥ 2 years